Back to Search
Start Over
Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules.
- Source :
-
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2006 Apr; Vol. 55 (4), pp. 355-62. Date of Electronic Publication: 2005 Sep 27. - Publication Year :
- 2006
-
Abstract
- Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.
- Subjects :
- Antineoplastic Agents immunology
Antineoplastic Agents pharmacology
Computational Biology
Genomics
Humans
Immunotherapy trends
Receptors, Tumor Necrosis Factor drug effects
Receptors, Tumor Necrosis Factor physiology
TNF-Related Apoptosis-Inducing Ligand
Tumor Necrosis Factor Ligand Superfamily Member 14
Tumor Necrosis Factor Receptor Superfamily, Member 9
Tumor Necrosis Factor-alpha physiology
Antigens, CD immunology
Apoptosis Regulatory Proteins immunology
CD40 Antigens immunology
Membrane Glycoproteins immunology
Membrane Proteins immunology
Neoplasms drug therapy
Neoplasms immunology
Receptors, Nerve Growth Factor immunology
Receptors, Tumor Necrosis Factor immunology
Tumor Necrosis Factor-alpha immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0340-7004
- Volume :
- 55
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Cancer immunology, immunotherapy : CII
- Publication Type :
- Academic Journal
- Accession number :
- 16187084
- Full Text :
- https://doi.org/10.1007/s00262-005-0081-y